èšåºæ®µéã®ãã€ãªãã¯ãããžãŒäŒæ¥ã§ãã Sangamo Therapeutics, Inc. ã¯ãéºäŒåæ²»çãçŽ°èæ²»çãã²ãã ç·šéãã²ãã 調ç¯ã®ãã©ãããã©ãŒã æè¡ã䜿çšããŠãç§åŠãæ£è
ã®ç掻ãå€ããã²ãã å»è¬åã«å€æããããšã«æ³šåããŠããŸããå瀟ã¯ãç¹å®ã®éºäŒåã®è¿œå ãŸãã¯ããã¯ã¢ãŠãããããã¯ã²ãã ç·šéã«ãã£ãŠ DNA é
åã倿Žããããã«äœ¿çšãããã¿ã³ãã¯è³ªã§ãããžã³ã¯ãã£ã³ã¬ãŒãã¯ã¬ã¢ãŒãŒãäœæããããã®æè¡ãã©ãããã©ãŒã ã§ãããžã³ã¯ãã£ã³ã¬ãŒã¿ã³ãã¯è³ª (ZFP)ãããã³éºäŒåçºçŸã®å¢å ãŸãã¯æžå°ã«äœ¿çšããã ZFP 転åå åã¿ã³ãã¯è³ªãæäŸããŠããŸããå瀟ã¯ãè¡åç
A ã®æ²»çã®ããã®ç¬¬ III çž AFFINE èšåºè©Šéšäžã® SB-525ããã¡ããªãŒç
ã®æ²»çã®ããã®ç¬¬ I/II çž STAAR èšåºè©Šéšäžã®éºäŒåæ²»ç ST-920ãéç¶èµ€è¡ççã®æ²»çã®ããã®ç¬¬ I/II çž PRECIZN-1 èšåºè©Šéšäžã®çŽ°èæ²»ç BIVV003 ãéçºããŠããŸãã ST-400 ã¯çްèçæ³ã§ã茞è¡äŸåæ§ããŒã¿ãµã©ã»ãã¢ã®æ²»çè¬ãšããŠã¿ã¬ã¹ç€Ÿã第 I/II çžèšåºè©Šéšãè¡ã£ãŠããŸãããŸããHLA-A2 äžäžèŽè
ç§»æ€æçµ¶åå¿ã®æ²»çè¬ã§ãããã¡ã©æååå®¹äœ TX200ãããæ²»ççšã®æ CD19 CAR-T 现èçæ³ã§ãã KITE-037 ãéçºããŠããŸãããã§ãã«ã±ãã³å°¿çã®éºäŒåçæ³ã§ãã ST-101 ãéçºããŠããŸããBiogen MA, Inc.ãKite Pharma, Inc.ãPfizer Inc.ãSanofi GenzymeãShire International GmbHãDow AgroSciences LLCãSigma-Aldrich CorporationãGenentech, Inc.ãOpen Monoclonal Technology, Inc.ãF. Hoffmann-La Roche Ltd ããã³ Hoffmann-La Roche Inc.ãCalifornia Institute for Regenerative Medicine ãšå
±åããã³æŠç¥çããŒãããŒã·ãããçµãã§ããŸããå瀟ã¯ä»¥åã¯Sangamo BioSciences, Inc.ãšããŠç¥ãããŠããŸãããã2017幎1æã«Sangamo Therapeutics, Inc.ã«ç€Ÿåã倿ŽããŸãããSangamo Therapeutics, Inc.ã¯1995幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ããªã¹ãã³ã«æ¬ç€Ÿã眮ããŠããŸãã